Objective: It has been repeatedly proven that statins improve endothelial function in isolated hypercholesterolaemia but there is far less evidence in the case of combined hyperlipidaemia. Studies assessing the effects of fibrates on endothelium have been neglected. Therefore, we conducted a trial in which the effects of fenofibrate and atorvastatin monotherapy on both endothelium-dependent vascular reactivity and biochemical parameters were compared in patients with combined hyperlipidaemia. Methods: 29 otherwise healthy males (aged 47.467.8 years) with combined hyperlipidaemia (total cholesterol 7.5561.20 mmol / l, triglycerides 5.4164.54 mmol / l) were included into the randomised, single-blind, cross-over study to receive either 200 mg of micronised fenofibrate or 10 mg of atorvastatin daily -each of the drugs for a period of 10 weeks. Analysed biochemical parameters were as follows: serum total-, LDL-and HDL-cholesterol, apolipoproteins A-I and B, triglycerides, fibrinogen, uric acid, C-reactive protein (CRP), insulin, and homocysteine. Endothelial function was investigated by duplex Doppler ultrasonography at the brachial artery. Two indices of endothelial-dependent postischaemic changes were used -the recently introduced index of peak blood flow (PBF) representing the level of reactive hyperaemia and traditional flow-mediated dilatation (FMD). Results: We observed a small improvement in FMD after both fenofibrate and atorvastatin (from 2.26% to 2.98% and 2.87%, respectively; NS). PBF increased from 448 ml / min to 536 ml / min after fenofibrate (P50.04) and to 570 ml / min after atorvastatin (P50.03). The effects of both fenofibrate and atorvastatin on endothelial function did not differ significantly (P-values of 0.82 and 0.47 for FMD and PBF, respectively). Significant correlations (P,0.01) between the changes of vascular reactivity and biochemical indices were found between FMD and CRP (r520.60) and between both FMD and PBF, and insulinaemia (r520.48 and 20.56, respectively) only during treatment with fenofibrate. Conclusions: Both fenofibrate and atorvastatin significantly improved endothelium-dependent vascular reactivity without mutual difference. The PBF was superior to FMD for the detection of this improvement. The beneficial effect of both drugs did not correlate with the change of lipid profile during therapy. The improvement of vascular reactivity during treatment with fenofibrate (opposed to atorvastatin) was related to the reduction of indirect marker of chronic vessel wall inflammation and of insulin resistance. The PBF was more reproducible than FMD because of considerably lower intra-subject variability.
Introduction
brachial artery assessed by ultrasound represents a frequently used non-invasive method [2] . Recent evidence There is growing evidence that endothelial dysfunction has suggested that the level of postischaemic hyperaemia precedes the development of atherosclerosis [1] in subjects assessed by Doppler ultrasound or by plethysmography, is with cardiovascular risk factors. Endothelium-dependent also related to endothelial function [3, 4] . The duplex vascular reactivity has been studied both in coronary and Doppler ultrasonography can be used for the simultaneous peripheral arteries. Flow-mediated dilatation (FMD) of assessment of both FMD and reactive hyperaemia. Major functional consequences of endothelial dysfunc-tion include reduced bioavailability of nitric oxide (NO) genotype were excluded. Since we found considerably [5] , increased expression of cytoadhesive molecules [6, 7] , high intra-subject variability of FMD contrasting to that of and of components involved in both thrombosis and Doppler indices (see Results and Discussion), the populafibrinolysis [8] . Several studies have documented endotion size was calculated in order to detect significant thelial dysfunction in subjects with isolated hypercholeschanges of reactive hyperaemia during medical interventerolaemia [9, 10] . The presence of highly atherogenic tion. small, dense LDL-particles, accompanying elevated triAfter the initial examination the participants were glycerides, was related to endothelial dysfunction in diarandomised into two groups. Group I (n515) received 200 betic patients [11] . The reports on the influence of elevated mg of micronised fenofibrate once daily for 10 weeks triglycerides on endothelium are controversial [12, 13] .
followed by 10 mg of atorvastatin once daily for the next Endothelial dysfunction was also observed in insulin 10 weeks. Group II (n514) received the same drugs but in resistant subjects [14] . Chronic vessel wall inflammation, the opposite way. The drugs were taken in the mornings widely studied recently [15] [16] [17] , was also closely related except on the days of examination to eliminate their acute to endothelial dysfunction. The levels of C-reactive protein effect. All participants were instructed not to change their (CRP), interleukin-6, and fibrinogen -the markers of dietary and drinking habits during the whole study and not chronic vessel wall inflammation [18] -were decreased to take any additional medication including vitamin supby lipid-lowering therapy [19] .
plements. A physical examination was performed, blood The treatment of isolated hypercholesterolaemia by samples taken and ultrasound examination were completed statins improved endothelial function [20, 21] . Only one during each visit at baseline, at cross-over, and at the end recent study has documented the improvement of endoof the study. thelial function by a fibrate [22] . However, this study was
In the absence of a parallel placebo group, a control performed in a population of diabetic subjects. Generally, group was constituted. Fifteen healthy male volunteers there is little data about the influence of lipid-lowering aged 34.867.2 years (range 29-50) without cardiovascular therapy on endothelial function in combined hyperrisk factors and any medication were recruited from the lipidaemia [23] .
hospital staff. Two ultrasound examinations were perThe most frequently used lipid-lowering drugs in comformed within 1 week using rigorously the same examinabined hyperlipidaemia are fibrates, statins (mainly atorvastion protocol as in patients. tatin), or combination of both. The dose of atorvastatin
The local ethical committee approved the design of the prescribed in clinical practice is usually much lower than study and all participants signed informed consent. The that in clinical trials, where up to 80 mg daily were study conformed to the principles outlined in the Declaraadministered [24] . It raises a question whether endothelial tion of Helsinki. dysfunction could be significantly improved by a standarddose lipid-lowering therapy.
We conducted a study in a population of patients with 3. Methods combined hyperlipidaemia, in which the effects of micronised fenofibrate (200 mg o.d.) and atorvastatin (10 mg o.d.)
3.1. Ultrasound examination protocol were compared. The primary objective of this study was to compare the effects of atorvastatin and fenofibrate on Ultrasound examination of vascular reactivity was perendothelium-dependent vascular reactivity. The secondary formed in fasting state (at least 12 h) in the morning objective was to investigate whether expected improve-(07:00-08:00 h). The subjects remained at rest in the ment of vascular reactivity is related to the drug-induced supine position for at least 15 min before the examination changes of lipid profile, insulinaemia or markers of chronic started. Subject's right arm was comfortably immobilised inflammation.
in the extended position to allow consistent recording of the brachial artery 2-4 cm above the antecubital fossa. The artery segment was imaged using a 7.5-MHz linear array 2. Patient population and study design ultrasound transducer (Hewlett-Packard, SONOS 2000, USA). A special transducer fixing device developed by R. Participants of the study were recruited from patients
Meijer from Utrecht University, The Netherlands, was referred to the university hospital-based lipid clinic. Only used to avoid arm or transducer movement and to mininon-smoking otherwise healthy males with non-treated mise examiner fatigue. The transducer was immersed into combined hyperlipidaemia (fasting plasma cholesterol a water-reservoir with a membrane-bottom that was also .6.2 mmol / l and triglycerides .1.5 mmol / l) were infixed to the device in order to ensure a constant pressure to cluded in the study. Subjects with secondary hyperthe artery. Ultrasound gain and the section plane were 2 lipidaemia, body mass index .32 kg / m , impaired gluoptimised to provide clear arterial wall interfaces. A cose tolerance (according to the oral glucose tolerance test modified protocol described by Celermajer was used [9] . prior to the inclusion), alcohol abuse or apo E2 / E2
After resting records of both B-mode and pulsed Doppler spectral curve, a sphygmomanometer cuff, placed around Blood flow was measured at rest and immediately after the the forearm distal to the imaged artery segment, was cuff release, as a mean of three cardiac cycles (excluding inflated to the pressure of 200 mmHg for 4.5 min. The the first, usually deformed cycle). Peak blood flow (PBF, spectral curve was taken immediately after the cuff release ml / min) in early post-ischaemic period was calculated as for 10 s. Then the ultrasound device was switched back to the velocity time integral multiplied by the vessel cross-B-mode and the recording continued for the next 5 min. sectional area. Blood flow increase (BFI) was calculated as All ultrasound images were stored on S-VHS videotape for the percentage increase of resting blood flow. subsequent off-line analysis.
3.4. Statistical methods
Biochemistry
For the randomisation, the dynamic allocation procedure All blood samples were collected in the morning hours was used, in which the allocation was influenced by the (07:00-08:00 h) after overnight fasting and processed current balance of pre-specified factors -age, T-C, TG, immediately. Total serum cholesterol (T-C), HDL cholesand body-mass index. All results are presented as terol (HDL-C), triglycerides (TG), and uric acid were means6standard deviations (S.D.). Comparison of the determined enzymatically using a multianalyser HITACHI effects of both drugs, period effect and carry-over effect 717 and commercially available kits. LDL cholesterol were tested using cross-over T statistics [26] . Unpaired-(LDL-C) was calculated according to the Friedewald's and paired t-test were used as appropriate. Pearson's formula and non-HDL-C as the difference of T-C and correlation was used to test the relationship between HDL-C. Serum levels of apolipoprotein AI (Apo AI) and absolute changes of biochemical parameters and of ultraapolipoprotein B (Apo B) were determined by Laurell's sound surrogates of vascular reactivity. The normal values rocket immunoelectrophoresis, using commercially availof ultrasound indices and their intra-subject repeatability able antisera (Immuno, Austria).
were calculated from control group. The intra-subject Plasma fibrinogen was determined according to Clauss repeatability was expressed as a mean of the coefficients of (Immuno, Austria). Serum CRP was determined by imvariation, which were separately calculated for each pair of munoturbidimetric assay using a commercially available values of FMD, PBF, and BFI obtained during both kit (Lachema, Czech Republic). Total serum homocysteine examinations. The inter-subject variability was calculated (HCY) was determined by a modification of the method as the standard deviation of differences between two developed by Araki and Sako [25] . The thiol compounds in measurements over the pooled mean of all measurements. serum were derivatised with SBD-F (a thiol-specific fluoro-
The intra-observer reproducibility of the measurement of genic reagent). The derivatives were separated and quanvessel diameter and mean blood velocity for both resting tified by reversed-phase high-performance liquid chromaand hyperaemia period were expressed as coefficient of tography using a HPLC Chrompack GRAS (Chrompack, variations which were calculated separately for every Holland) apparatus and fluorescence detector FL 2000 subgroup of readings consisting of six measurements in six (SP-Thermo, Separation Products, California). Fasting consecutive heart cycles in all available records. serum insulin was determined by RIA method using a
The study was designed to detect a 20% change of PBF commercially available kit (CIS Bio International, France).
at the 5% significance level (a55%, two-sided) with 80% power. Minimum sample size was calculated by nQuery 3.3. Image processing Advisor, v. 4.0 (Statistical Solutions, USA) on the basis of the estimate of inter-subject variability in the control All ultrasound images stored on videotapes were exgroup. amined off-line by a single observer blinded to the randomisation code and biochemical data. Digitised Bmode scans were analysed using the Image-Pro Plus 4. Results software, v. 4.0 (Media-Cybernetics, L.P.) with automatic border detection function. The perpendicular distance It was calculated that 16 patients would be needed to between the M-lines was measured at end-diastole detected prove the change of PBF. As 29 males were enrolled into by the R wave of a single precordial ECG lead. The the study, the power of the study increased to 98%. averaged value of vessel diameter was calculated from six Baseline characteristics of total population were as fol-2 resting cycles taken before the cuff inflation and from six lows: age 47.467.8 years, BMI 27.862.7 kg / m , systolic post-ischaemic cycles within the interval of 60-80 s after blood pressure 124.8612.0 mmHg, and diastolic blood cuff release. Flow-mediated dilatation (FMD) was expressure 82.366.9 mmHg. pressed as the percentage of postischaemic increase of the There were neither drop-outs from the study nor serious resting diameter. adverse events. Two participants complained of mild The pulsed-Doppler spectral scans were analysed using abdominal pain when receiving atorvastatin and discona built-in electronic calliper of the ultrasound device.
tinued the treatment for 2 and 3 days, respectively. Safety screening biochemistry (including creatin-phosphokinase significantly after atorvastatin, while its increase after and transaminases) did not change significantly during the fenofibrate reached a borderline statistical significance. trial.
Biochemical parameters

Ultrasound characteristics of endothelial function
The results of biochemical analysis are shown in Table  2 . Atorvastatin was superior to fenofibrate in reducing In the group of healthy volunteers, the indices of serum T-C, LDL-C and non-HDL-C. Fenofibrate was more vascular reactivity were as follows: PBF 896.36251.8 efficient in reducing serum TG and in elevating HDL-C, ml / min, BFI 550.96190.0%, and FMD 4.7562.52%. The although the beneficial effect of both drugs on Apo-AI was intra-subject repeatability was 12.8, 24.5, and 41.0%, for comparable. Both drugs decreased CRP and insulinaemia. PBF, BFI, and FMD, respectively. The inter-subject variHowever, this decrease was statistically significant only for ability of differences was 25.3, 40.5, and 59.1% for PBF, fenofibrate. Adverse effects of both fenofibrate and ator-BFI and FMD, respectively. The intra-observer reprovastatin were observed -increase in homocysteine after ducibility was 0.87, 3.7, and 1.8% for the measurement of fenofibrate and increase in fibrinogen after atorvastatin. vessel diameter, mean blood velocity at rest and during hyperaemia, respectively.
Correlation of biochemical parameters and indices
In patients, only three of 87 ultrasound B-mode records of vascular reactivity and nine of 87 spectral records had insufficient quality for the assessment of FMD and indices of blood flow, At baseline, the only significant correlation between respectively. The results are shown in Table 1 . There were biochemical and ultrasound parameters was found for CRP no differences between drugs in all ultrasound parameters. and FMD (negative relationship) as we reported elsewhere We observed only a trend in FMD to increase after both [27] . drugs. On the contrary, significant post-treatment changes Analysis of the effects of treatment revealed significant of indices of reactive hyperaemia were observed. PBF correlation between the decrease of both CRP and inincreased significantly after both drugs. BFI increased sulinaemia and the improvement of vascular reactivity Paired t-test was used for evaluation of effects of both drugs: P-values *,0.05; **,0.005; ***,0.001. Cross-over T-statistics were used for between-drugs comparison: P-values (F vs. A) are given in exact numbers; n.s., non-significant (P.0.05).
a LDL calculation according to Friedewald's formula was possible in 18 blood samples at baseline, in 26 blood samples after fenofibrate and in 24 blood samples after atorvastatin. during treatment with fenofibrate (Table 3 , Figs. 1-3 ). The improvement of vascular reactivity was not significantly correlated with the change of lipid parameters for both drugs.
Carry-over and period effect
The carry-over, i.e. the drug-specific effect, the presence of which means that treatment with one drug in the first period of cross-over trial influences the effect of subsequently used alternate drug, was not observed for any of the biochemical and ultrasound parameters. The period effect, i.e. the effect of intervention on a particular parameter (assessed in the whole population and irrespective of drug used) at cross-over is different from that at the end of the study, was found for insulinaemia. The level of serum insulin was 24.268.2 mU / l at cross-over and further decreased to 21.967.0 at the final visit (P5 0.032).
Discussion
The study was designed to investigate the changes of vascular reactivity during lipid-lowering therapy with drugs from different classes in patients with combined hyperlipidaemia and to find out the relations between vascular reactivity and biochemical parameters.
The detrimental vascular effect of hypertriglyceridaemia is mainly explained by the preponderance of atherogenic small, dense LDL particles, that was proved for triglyceride levels above 1.5 mmol / l [28] . Consequently, we chose this relatively low cut-off point of TG for inclusion into the study. Relatively high baseline levels of CRP Based on our assessment of repeatability, some previous studies using FMD were underpowered due to small sample size. Therefore we decided to study the vascular tion, nor other metabolic effects of atorvastatin, was reactivity primarily by PBF with the appropriate presignificantly related to the changes of vascular reactivity in determined sample size. As FMD is widely used and gives our study. Lack of correlation between the increase of easily assessed Doppler indices, we left it as a part of the FMD and the reduction of T-C and LDL-C was already study protocol to reveal whether at least the trend in its described by others [31] . These findings may support the improvement will appear. theory of non-lipid effects of statins including their Although the drugs studied differed in metabolic action, influence on the monocyte-macrophage system and inhibitheir effects on vascular reactivity were similar.
tion of the expression of cytoadhesive molecules [32] . Atorvastatin decreased T-C and non-HDL-C signifiFenofibrate decreased triglycerides, CRP and increased cantly more than fenofibrate. In previous studies, the HDL-C significantly more than atorvastatin. Fenofibrate statins directly decreased the expression of endothelin-1 did not increase plasma fibrinogen in comparison to and increased the activity of endothelial NO-synthase [29] , atorvastatin. Fenofibrate also significantly reduced inimproved endothelial function [20] in isolated hypercholessulinaemia, although this effect was not significantly terolaemia and in hypertriglyceridaemia, and generally different from that of atorvastatin. As we have demonreduced the mortality [30] . Neither the cholesterol reducstrated earlier, there is no difference between the effect of fenofibrate and atorvastatin on mean LDL-particle size 6. Limitations [33] .
It has been documented by other authors that high This trial compared the effects of two lipid-lowering triglycerides [12] , increased CRP [17], elevated indrugs in a group of 29 males with moderate combined sulinaemia [14], low HDL-C and low mean LDL particle hyperlipidaemia. The endothelium-dependent vascular [11] size are all separately associated with endothelial reactivity was investigated by a non-invasive method. dysfunction. The pleiotropic metabolic action of fenofibStrong evidence is missing that similar changes may occur rate that is mediated through peroxisome-proliferator-actiin other parts of the arterial tree (e.g. coronary arteries). vated receptor (PPAR) alpha could therefore partly explain However, a non-invasive method is relatively cheap and the effect of fenofibrate on vascular reactivity [34] . Howeasily repeatable for studying the treatment effects in ever, in our study, the changes of vascular reactivity were 'primary prevention' patients. The power of the study was significantly related only to the changes of CRP and calculated to detect change in PBF, but not for FMD. insulinaemia.
We tested treatment effects on 15 variables and were The analysis of the period effect suggests that the insulin aware of the problem of multiple testing. However, even resistance in combined hyperlipidaemia continues to imafter Bonferroni [38] adjustment was used, changes in prove during lipid-lowering therapy beyond the treatment biochemical variables remained significant. Similar probperiod of 10 weeks. However, our data do not authorise us lems were related to the correlations. Therefore, we to conclude whether this observation is inherent to fenofibaccepted only those having a stricter P-value (below 0.01). rate, atorvastatin, or both drugs.
The number of patients was not sufficient for reliable Vascular reactivity was studied by three variablescalculation of all links between changes of vascular FMD, PBF and BFI. Others have already used PBF and reactivity and metabolic changes. Probably for this reason BFI for the assessment of vascular reactivity [35] , but until the significant correlation between cholesterol decrease and lately these indices have not been fully accepted as vascular reactivity improvement was not proven. markers of endothelial function [36] . Recently, it was
The study was primarily designed to compare effects of proven that PBF correlates tightly with the flow changes two lipid-lowering drugs. Therefore, no parallel placebo induced by intraarterial infusion of acetylcholine, a method group was included. On the other hand, placebo effect is widely accepted for the assessment of endothelial function unlikely to occur for biochemical parameters and the [3, 4] . Opposed to FMD, the parameters of blood flow spontaneous improvement of ultrasound indices was not reflect 'mean' vascular reactivity of a relatively large observed in the control group. However, the subjects of portion of the arterial tree. This is probably the basis of control group were recruited from the population of their robustness and better intra-subject repeatability in healthy and younger people and the findings in this group comparison to FMD. BFI is apparently less reproducible may not be valid for the group of patients with combined than PBF because it represents a relative number, in which hyperlipidaemia. two measurement errors (of resting and hyperaemic phase) Target goal levels of cholesterol and triglycerides recare incorporated.
ommended by guidelines were not achieved due to relaThe observation of low repeatability of FMD is in tively low doses of trial medications. Therefore, more contradiction with some previous reports. However, others intensive treatment could lead to more pronounced imhave found even worse reproducibility of this parameter provement of endothelial function. The period of 10 weeks (CV above 50%) [37] . As the optimum experimental appeared to be sufficient to reach the maximum effect for settings (experienced examiner, fixing device, and comall parameters, except for insulinaemia, in which a longer puter assisted tracking of vessel wall) was used and intraperiod of treatment might probably cause a more promiobserver reproducibility of measurement of vessel diameter nent effect. Although the carry-over effect can occur in the measurement was low, the major source of high intracross-over trial design, it was not confirmed statistically. subject variability of FMD is obviously due to its high Thus, missing the washout period at cross-over should not spontaneous variability. It can be explained by the fact that have influenced the final results and 10 weeks of the FMD reflects both the local increase of wall shear stress second period of treatment was sufficiently long not to due to the increase of blood flow velocity in hyperaemic 'carry' the effect of the drug used in the first period. phase and the ability of the arterial segment to respond to this change by its dilation. Therefore its variability depends on both variability of postischaemic hyperaemia and 7. Conclusions variability of local response. The considerable number of published 'positive' findings in small groups of patients This trial was designed to compare the effects of could be partly explained by the 'publication bias'. A fenofibrate and atorvastatin, given at standard doses, on larger study of FMD repeatability is needed to explain endothelium function. 
